Sales & Marketing News | pharmaphorum

News

GSK reprimanded over "shocking error" in Omjjara info

A complaint against GSK alleging a major breach of the pharma industry's code of practice on prescribing information has been upheld by the PMCPA.

News

There's good news for RSV jab firms at delayed ACIP meeting

GSK and Pfizer could see a resurgence in sales of their RSV vaccines if new recommendations at a CDC expert meeting are confirmed by agency leaders.

News

FDA clears first migraine DTx from Click Therapeutics

Click Therapeutics' digital therapeutic (DTx) for migraine prevention has been cleared by the FDA, becoming the first treatment of its type in the US.

News

Trump pledges drug price cuts – and action on 'pill penalty'

A Trump executive order aimed at lowering drug prices includes a plan to do away with what industry claims is a flaw in the Inflation Reduction Act.

News

J&J expecting $400m hit from tariffs in 2025

J&J chief executive Joaquin Duato has told analysts that tax policy, not tariffs, is the key to increasing pharma manufacturing capacity in the US.

News

After delay, Alzheimer's drug Leqembi gets green light in EU

The EU has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, more than two years after it was filed.

GSK reprimanded over "shocking error" in Omjjara info

There's good news for RSV jab firms at delayed ACIP meeting

FDA clears first migraine DTx from Click Therapeutics

Trump pledges drug price cuts – and action on 'pill penalty'

J&J expecting $400m hit from tariffs in 2025

After delay, Alzheimer's drug Leqembi gets green light in EU

Nuvalent buy delivers new cancer approval for GSK

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks